{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:12:42Z","timestamp":1787163162973,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00120-025-02661-y","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:49:49Z","timestamp":1756288189000},"page":"1093-1104","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PSMA-Radioligandentherapie \u2013 State of the Art","PSMA radioligand therapy\u2014State of the art"],"prefix":"10.1007","volume":"64","author":[{"given":"Christoph","family":"Berliner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Krafft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Himmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang P.","family":"Fendler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"2661_CR1","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","volume":"402","author":"N Agarwal","year":"2023","unstructured":"Agarwal\u00a0N, Azad\u00a0AA, Carles\u00a0J et\u00a0al (2023) Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a\u00a0randomised, placebo-controlled, phase\u00a03\u00a0trial. Lancet 402:291\u2013303. https:\/\/doi.org\/10.1016\/S0140-6736(23)01055-3","journal-title":"Lancet"},{"key":"2661_CR2","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","volume":"25","author":"AA Azad","year":"2024","unstructured":"Azad\u00a0AA, Bressel\u00a0M, Tan\u00a0H et\u00a0al (2024) Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a\u00a0multicentre, open-label, randomised, phase\u00a02\u00a0study. Lancet Oncol 25:1267\u20131276. https:\/\/doi.org\/10.1016\/S1470-2045(24)00440-6","journal-title":"Lancet Oncol"},{"key":"2661_CR3","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","volume":"23","author":"JP Buteau","year":"2022","unstructured":"Buteau\u00a0JP, Martin\u00a0AJ, Emmett\u00a0L et\u00a0al (2022) PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a\u00a0biomarker analysis from a\u00a0randomised, open-label, phase\u00a02\u00a0trial. Lancet Oncol 23:1389\u20131397. https:\/\/doi.org\/10.1016\/S1470-2045(22)00605-2","journal-title":"Lancet Oncol"},{"key":"2661_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2025.04.012","author":"KN Chi","year":"2025","unstructured":"Chi\u00a0KN, Castro\u00a0E, Attard\u00a0G et\u00a0al (2025) Niraparib and Abiraterone Acetate plus Prednisone in metastatic castration-resistant prostate cancer: final overall survival analysis for the phase\u00a03 MAGNITUDE trial. Eur Urol Oncol. https:\/\/doi.org\/10.1016\/j.euo.2025.04.012","journal-title":"Eur Urol Oncol"},{"key":"2661_CR5","doi-asserted-by":"publisher","first-page":"TPS5087","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5087","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi\u00a0KN, Metser\u00a0U, Czernin\u00a0J et\u00a0al (2021) Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using177 Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH). J\u00a0Clin Oncol 39:TPS5087\u2013TPS5087. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.TPS5087","journal-title":"J Clin Oncol"},{"key":"2661_CR6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.euo.2024.09.013","volume":"8","author":"NW Clarke","year":"2025","unstructured":"Clarke\u00a0NW, Armstrong\u00a0AJ, Oya\u00a0M et\u00a0al (2025) Efficacy and safety of Olaparib plus Abiraterone versus placebo plus Abiraterone in the first-line treatment of patients with asymptomatic\/mildly symptomatic and symptomatic metastatic castration-resistant prostate cancer: analyses from the phase\u00a03 PROpel trial. Eur Urol Oncol 8:394\u2013406. https:\/\/doi.org\/10.1016\/j.euo.2024.09.013","journal-title":"Eur Urol Oncol"},{"key":"2661_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.eururo.2023.08.026","volume":"85","author":"RS Eapen","year":"2024","unstructured":"Eapen\u00a0RS, Buteau\u00a0JP, Jackson\u00a0P et\u00a0al (2024) Administering [177Lu]Lu-PSMA-617 prior to radical prostatectomy in men with high-risk Localised prostate cancer (LuTectomy): a\u00a0single-centre, single-arm, phase\u00a01\/2\u00a0study. Eur Urol 85:217\u2013226. https:\/\/doi.org\/10.1016\/j.eururo.2023.08.026","journal-title":"Eur Urol"},{"key":"2661_CR8","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett\u00a0L, Subramaniam\u00a0S, Crumbaker\u00a0M et\u00a0al (2024) [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 25:563\u2013571. https:\/\/doi.org\/10.1016\/S1470-2045(24)00135-9","journal-title":"Lancet Oncol"},{"key":"2661_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00009-9","author":"L Emmett","year":"2025","unstructured":"Emmett\u00a0L, Subramaniam\u00a0S, Crumbaker\u00a0M et\u00a0al (2025) Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a\u00a0multicentre, open-label, randomised, phase\u00a02\u00a0trial. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(25)00009-9","journal-title":"Lancet Oncol"},{"key":"2661_CR10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1470-2045(23)00158-4","volume":"24","author":"K Fizazi","year":"2023","unstructured":"Fizazi\u00a0K, Herrmann\u00a0K, Krause\u00a0BJ et\u00a0al (2023) Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a\u00a0multicentre, open-label, randomised, phase\u00a03\u00a0trial. Lancet Oncol 24:597\u2013610. https:\/\/doi.org\/10.1016\/S1470-2045(23)00158-4","journal-title":"Lancet Oncol"},{"key":"2661_CR11","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","volume":"22","author":"A Gafita","year":"2021","unstructured":"Gafita\u00a0A, Calais\u00a0J, Grogan\u00a0TR et\u00a0al (2021) Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol 22:1115\u20131125. https:\/\/doi.org\/10.1016\/S1470-2045(21)00274-6","journal-title":"Lancet Oncol"},{"key":"2661_CR12","doi-asserted-by":"publisher","first-page":"34930","DOI":"10.18632\/oncotarget.9004","volume":"7","author":"TM Gorges","year":"2016","unstructured":"Gorges\u00a0TM, Riethdorf\u00a0S, von Ahsen\u00a0O et\u00a0al (2016) Heterogeneous PSMA expression on circulating tumor cells: a\u00a0potential basis for stratification and monitoring of PSMA-directed therapies in prostate cancer. Oncotarget 7:34930\u201334941. https:\/\/doi.org\/10.18632\/oncotarget.9004","journal-title":"Oncotarget"},{"key":"2661_CR13","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","volume":"75","author":"MM Heck","year":"2019","unstructured":"Heck\u00a0MM, Tauber\u00a0R, Schwaiger\u00a0S et\u00a0al (2019) Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer. Eur Urol 75:920\u2013926. https:\/\/doi.org\/10.1016\/j.eururo.2018.11.016","journal-title":"Eur Urol"},{"key":"2661_CR14","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman\u00a0MS, Emmett\u00a0L, Sandhu\u00a0S et\u00a0al (2021) [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet 397:797\u2013804. https:\/\/doi.org\/10.1016\/S0140-6736(21)00237-3","journal-title":"Lancet"},{"key":"2661_CR15","first-page":"927","volume":"7","author":"JS Horoszewicz","year":"1987","unstructured":"Horoszewicz\u00a0JS, Kawinski\u00a0E, Murphy\u00a0GP (1987) Monoclonal antibodies to a\u00a0new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 7:927\u2013935","journal-title":"Anticancer Res"},{"key":"2661_CR16","doi-asserted-by":"publisher","first-page":"175883592311576","DOI":"10.1177\/17588359231157632","volume":"15","author":"A Jang","year":"2023","unstructured":"Jang\u00a0A, Kendi\u00a0AT, Sartor\u00a0O (2023) Status of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials. Ther Adv Med Oncol 15:17588359231157632. https:\/\/doi.org\/10.1177\/17588359231157632","journal-title":"Ther Adv Med Oncol"},{"key":"2661_CR17","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(24)00326-7","volume":"25","author":"MJ Karpinski","year":"2024","unstructured":"Karpinski\u00a0MJ, H\u00fcsing\u00a0J, Claassen\u00a0K et\u00a0al (2024) Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a\u00a0multicentre retrospective study. Lancet Oncol 25:1188\u20131201. https:\/\/doi.org\/10.1016\/S1470-2045(24)00326-7","journal-title":"Lancet Oncol"},{"key":"2661_CR18","doi-asserted-by":"publisher","first-page":"7645","DOI":"10.7150\/thno.44556","volume":"10","author":"K Kessel","year":"2020","unstructured":"Kessel\u00a0K, Seifert\u00a0R, Weckesser\u00a0M et\u00a0al (2020) Molecular analysis of circulating tumor cells of metastatic castration-resistant prostate cancer patients receiving 177Lu-PSMA-617 radioligand therapy. Theranostics 10:7645\u20137655. https:\/\/doi.org\/10.7150\/thno.44556","journal-title":"Theranostics"},{"key":"2661_CR19","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00259-019-04612-0","volume":"47","author":"F Khreish","year":"2020","unstructured":"Khreish\u00a0F, Ebert\u00a0N, Ries\u00a0M et\u00a0al (2020) 225Ac-PSMA-617\/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. Eur J Nucl Med Mol Imaging 47:721\u2013728. https:\/\/doi.org\/10.1007\/s00259-019-04612-0","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2661_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12081926","author":"T Langbein","year":"2022","unstructured":"Langbein\u00a0T, Kulkarni\u00a0HR, Schuchardt\u00a0C et\u00a0al (2022) Salivary gland toxicity of PSMA-targeted radioligand therapy with 177Lu-PSMA and combined 225ac- and 177Lu-labeled PSMA Ligands (TANDEM-PRLT) in advanced prostate cancer: a\u00a0single-center systematic investigation. Diagnostics. https:\/\/doi.org\/10.3390\/diagnostics12081926","journal-title":"Diagnostics"},{"key":"2661_CR21","first-page":"3629","volume":"57","author":"H Liu","year":"1997","unstructured":"Liu\u00a0H, Moy\u00a0P, Kim\u00a0S et\u00a0al (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 57:3629\u20133634","journal-title":"Cancer Res"},{"key":"2661_CR22","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris\u00a0MJ, Castellano\u00a0D, Herrmann\u00a0K et\u00a0al (2024) 177Lu-PSMA-617 versus a\u00a0change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a\u00a0phase\u00a03, randomised, controlled trial. Lancet 404:1227\u20131239. https:\/\/doi.org\/10.1016\/S0140-6736(24)01653-2","journal-title":"Lancet"},{"key":"2661_CR23","doi-asserted-by":"publisher","first-page":"TPS5100","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS5100","volume":"40","author":"JT Nauseef","year":"2022","unstructured":"Nauseef\u00a0JT, Osborne\u00a0J, Gregos\u00a0P et\u00a0al (2022) Phase\u00a0I\/II study of225 Ac-J591 plus177 Lu-PSMA-I&T for progressive metastatic castration-resistant prostate cancer. J\u00a0Clin Oncol 40:TPS5100\u2013TPS5100. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.TPS5100","journal-title":"J Clin Oncol"},{"key":"2661_CR24","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.21037\/tcr-23-1515","volume":"12","author":"J Panzone","year":"2023","unstructured":"Panzone\u00a0J, Rood\u00a0GJ, Goldberg\u00a0H (2023) The growing role of PARP inhibitors in the treatment of metastatic castration-resistant prostate cancer. Transl Cancer Res 12:3233\u20133240. https:\/\/doi.org\/10.21037\/tcr-23-1515","journal-title":"Transl Cancer Res"},{"key":"2661_CR25","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1186\/s13063-021-05733-4","volume":"22","author":"BM Priv\u00e9","year":"2021","unstructured":"Priv\u00e9\u00a0BM, Janssen\u00a0MJR, van Oort\u00a0IM et\u00a0al (2021) Update to a\u00a0randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial. Trials 22:768. https:\/\/doi.org\/10.1186\/s13063-021-05733-4","journal-title":"Trials"},{"key":"2661_CR26","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1158\/1078-0432.CCR-20-4298","volume":"27","author":"BM Priv\u00e9","year":"2021","unstructured":"Priv\u00e9\u00a0BM, Peters\u00a0SMB, Muselaers\u00a0CHJ et\u00a0al (2021) Lutetium-177-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer: a\u00a0prospective pilot study. Clin Cancer Res 27:3595\u20133601. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-4298","journal-title":"Clin Cancer Res"},{"key":"2661_CR27","doi-asserted-by":"publisher","first-page":"4050","DOI":"10.7150\/thno.56211","volume":"11","author":"F Rosar","year":"2021","unstructured":"Rosar\u00a0F, Hau\u00a0F, Bartholom\u00e4\u00a0M et\u00a0al (2021) Molecular imaging and biochemical response assessment after a\u00a0single cycle of [225Ac]Ac-PSMA-617\/[177Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [177Lu]Lu-PSMA-617 monotherapy. Theranostics 11:4050\u20134060. https:\/\/doi.org\/10.7150\/thno.56211","journal-title":"Theranostics"},{"key":"2661_CR28","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1007\/s00259-020-05057-6","volume":"48","author":"EAM Ruigrok","year":"2021","unstructured":"Ruigrok\u00a0EAM, van Vliet\u00a0N, Dalm\u00a0SU et\u00a0al (2021) Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy. Eur J Nucl Med Mol Imaging 48:1339\u20131350. https:\/\/doi.org\/10.1007\/s00259-020-05057-6","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2661_CR29","doi-asserted-by":"publisher","first-page":"S626","DOI":"10.1016\/j.annonc.2021.08.1090","volume":"32","author":"SK Sandhu","year":"2021","unstructured":"Sandhu\u00a0SK, Joshua\u00a0AM, Emmett\u00a0L et\u00a0al (2021) 577O PRINCE: Interim analysis of the phase\u00a0Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC). Ann Oncol 32:S626\u2013S627. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.1090","journal-title":"Ann Oncol"},{"key":"2661_CR30","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor\u00a0O, de Bono\u00a0J, Chi\u00a0KN et\u00a0al (2021) Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N\u00a0Engl J Med 385:1091\u20131103. https:\/\/doi.org\/10.1056\/NEJMoa2107322","journal-title":"N Engl J Med"},{"key":"2661_CR31","doi-asserted-by":"publisher","first-page":"S1254","DOI":"10.1016\/j.annonc.2024.08.2308","volume":"35","author":"O Sartor","year":"2024","unstructured":"Sartor\u00a0O, Jiang\u00a0DM, Smoragiewicz\u00a0M et\u00a0al (2024) LBA65 Efficacy of 177Lu-PNT2002 in PSMA-positive mCRPC following progression on an androgen-receptor pathway inhibitor (ARPI) (SPLASH). Ann Oncol 35:S1254\u2013S1255. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2308","journal-title":"Ann Oncol"},{"key":"2661_CR32","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.2967\/jnumed.121.262713","volume":"63","author":"C Schuchardt","year":"2022","unstructured":"Schuchardt\u00a0C, Zhang\u00a0J, Kulkarni\u00a0HR et\u00a0al (2022) Prostate-specific membrane antigen radioligand therapy using 177Lu-PSMA I&T and 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: comparison of safety, Biodistribution, and dosimetry. J\u00a0Nucl Med 63:1199\u20131207. https:\/\/doi.org\/10.2967\/jnumed.121.262713","journal-title":"J Nucl Med"},{"key":"2661_CR33","doi-asserted-by":"publisher","first-page":"TPS5116","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5116","volume":"41","author":"ST Tagawa","year":"2023","unstructured":"Tagawa\u00a0ST, Sartor\u00a0AO, Saad\u00a0F et\u00a0al (2023) PSMAddition: a\u00a0phase\u00a03\u00a0trial to compare treatment with177 Lu-PSMA-617 plus standard of care (SoC) and SoC alone in patients with metastatic hormone-sensitive prostate cancer. J\u00a0Clin Oncol 41:TPS5116\u2013TPS5116. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS5116","journal-title":"J Clin Oncol"},{"key":"2661_CR34","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1002\/cncr.32072","volume":"125","author":"ST Tagawa","year":"2019","unstructured":"Tagawa\u00a0ST, Vallabhajosula\u00a0S, Christos\u00a0PJ et\u00a0al (2019) Phase\u00a01\/2\u00a0study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (177 Lu-J591) for metastatic castration-resistant prostate cancer. Cancer 125:2561\u20132569. https:\/\/doi.org\/10.1002\/cncr.32072","journal-title":"Cancer"},{"key":"2661_CR35","doi-asserted-by":"publisher","first-page":"S975","DOI":"10.1016\/j.annonc.2024.08.1697","volume":"35","author":"SH Tolmeijer","year":"2024","unstructured":"Tolmeijer\u00a0SH, Kwan\u00a0EM, Ng\u00a0SWS et\u00a0al (2024) 1616P Circulating tumour DNA (ctDNA) measurements and PET-imaging to evaluate response in a\u00a0phase\u00a0Ib trial of metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177-PSMA-617 (LuPSMA) plus pembrolizumab (PRINCE). Ann Oncol 35:S975\u2013S976. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.1697","journal-title":"Ann Oncol"},{"key":"2661_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.05.011","author":"B Tombal","year":"2025","unstructured":"Tombal\u00a0B, Choudhury\u00a0A, Saad\u00a0F et\u00a0al (2025) Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3\u00a0trial. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2025.05.011","journal-title":"Ann Oncol"},{"key":"2661_CR37","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1007\/s00259-022-05974-8","volume":"50","author":"L Widjaja","year":"2023","unstructured":"Widjaja\u00a0L, Werner\u00a0RA, Krischke\u00a0E et\u00a0al (2023) Individual radiosensitivity reflected by \u03b3\u2011H2AX and 53BP1 foci predicts outcome in PSMA-targeted radioligand therapy. Eur J Nucl Med Mol Imaging 50:602\u2013612. https:\/\/doi.org\/10.1007\/s00259-022-05974-8","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2661_CR38","unstructured":"Uroweb EAU Guidelines: Prostate Cancer. https:\/\/uroweb.org\/guideline\/prostate-cancer\/. Zugegriffen: 14. Jan. 2025"},{"key":"2661_CR39","unstructured":"S3-Leitlinie Prostatakarzinom. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/043-022OL. Zugegriffen: 18. Febr. 2025"},{"key":"2661_CR40","unstructured":"ECLIPSE Trial. https:\/\/clinicaltrials.gov\/study\/NCT05204927. Zugegriffen: 18. Febr. 2025"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02661-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-025-02661-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-025-02661-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T06:29:47Z","timestamp":1759386587000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-025-02661-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2661"],"URL":"https:\/\/doi.org\/10.1007\/s00120-025-02661-y","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]},"assertion":[{"value":"9 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"C.\u00a0Berliner:\n                      A. Finanzielle Interessen: Advanced Accelerator Applications, einem Unternehmen der Novartis-Gruppe, sowie von GE Healthcare und Janssen. \u2013 B. Nichtfinanzielle Interessen: Dr. med. Christoph Berliner, Oberarzt, Standortleitung Duisburg, Universit\u00e4tsklinikum Essen (A\u00f6R), Klinik f\u00fcr Nuklearmedizin, Standort: Duisburg am Bethesda Krankenhaus, Eingang: K\u00f6niggr\u00e4tzer Stra\u00dfe | Mitgliedschaften: DGN, ESR, DGR, BDN.\n                      V.\u00a0Gr\u00fcnwald:\n                      A. Finanzielle Interessen: Research Grant, Financial interest, Institutional: AstraZeneca, BMS, MSD, Ipsen, Pfizer | | . \u2013 Travel support: Ipsen, Johnson & Johnson, Merck, Pfizer. \u2013 Invited Speaker, Personal: \u00a0Amgen, AstraZeneca, Astellas, BMS, EISAI, Ipsen, Johnson & Johnson, Merck, MSD, Pfizer, Novartis\/AAA, Telix Pharmaceutical, Roche; Advisory Board, Personal: BMS, EISAI, Ipsen, Debiopharm, Gilead, Johnson & Johnson, Merck, MSD, Novartis, Oncorena, Recordati, Synthekine; Stocks\/Shares, Personal: Amgen, AstraZeneca, BMS, Bicycle Therapeutics, MSD, Genmab. \u2013 Patente, Gesch\u00e4ftsanteile, Aktien o.\u00e4. an einer im Medizinbereich aktiven Firma: Amgen, AstraZeneca, BMS, Bicycle Therapeutics, MSD, Genmab. \u2013 B. Nichtfinanzielle Interessen: Membership: ASCO, ESMO, German medical Oncology and Hematology Society | Beraterrolle: German Cancer Society | F\u00fchrungsrolle: Working Group medical oncology (AIO).\n                      U.\u00a0Krafft:\n                      A. Finanzielle Interessen: IIT Funding: BMS, Novartis. \u2013 Kostenerstattung und Honorar: Novartis, Ipsen, Janssen, Roche. \u2013 Bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u00e4.: Novartis. \u2013 B. Nichtfinanzielle Interessen: Angestellte:r Urologe, Universit\u00e4tsklinik Essen.\n                      S.\u00a0Himmen:\n                      A. Finanzielle Interessen: Novartis, Siemens Healthineers, ABX (advanced biochemical compounds GmbH). \u2013 B. Nichtfinanzielle Interessen: Angestellter Facharzt f\u00fcr Nuklearmedizin (als Oberarzt) in der Klinik f\u00fcr Nuklearmedizin des Universit\u00e4tsklinikums Essen, Hufelandstr. 55, 45147 Essen | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Nuklearmedizin (DGN), European Association of Nuclear Medicine (EANM).\n                      W.\u00a0Fendler:\n                      A. Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Wolfgang P. Fendler reports fees from SOFIE Bioscience (research funding), Janssen (consultant, speaker), Perceptive (consultant, image review), Bayer (consultant, speaker, research funding), Novartis (speaker, consultant), Telix (speaker), GE Healthcare (speaker, consultant), Eczac\u0131ba\u015f\u0131 Monrol (speaker), Abx (speaker), Amgen (speaker, research funding), Urotrials (speaker), Lilly (consultant), AstraZeneca (research funding) outside of the submitted work. \u2013 Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: Wolfgang P. Fendler reports fees from SOFIE Bioscience (research funding), Janssen (consultant, speaker), Perceptive (consultant, image review), Bayer (consultant, speaker, research funding), Novartis (speaker, consultant), Telix (speaker), GE Healthcare (speaker, consultant), Eczac\u0131ba\u015f\u0131 Monrol (speaker), Abx (speaker), Amgen (speaker, research funding), Urotrials (speaker), Lilly (consultant), AstraZeneca (research funding) outside of the submitted work. \u2013 Bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u00e4.: Wolfgang P. Fendler reports fees from SOFIE Bioscience (research funding), Janssen (consultant, speaker), Perceptive (consultant, image review), Bayer (consultant, speaker, research funding), Novartis (speaker, consultant), Telix (speaker), GE Healthcare (speaker, consultant), Eczac\u0131ba\u015f\u0131 Monrol (speaker), Abx (speaker), Amgen (speaker, research funding), Urotrials (speaker), Lilly (consultant), AstraZeneca (research funding) outside of the submitted work. \u2013 B. Nichtfinanzielle Interessen: Mitgliedschaften: EAU, EANM, SNMMI, ASCO.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      . Der Verlag erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}